Neuropsychiatric involvement in systemic lupus erythematosus. Part 1: Clinical presentation and pathogenesis;Neuropsychiatrische beteiligung des systemischen lupus erythematodes: Teil 1: Klinik und pathogenese

Medizinische Klinik

Volumn 97, Issue 12, 2002, Pages 730-737

  Weiner, Stefan Markus ^b   Peter, Hans Hartmut ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Central nervous system involvement; Clinical sympton; Pathogenesis; SLE, neuropsychiatric; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CYTOKINE; GLYCINE CLEAVAGE SYSTEM; PHOSPHOLIPID ANTIBODY; RIBOSOME PROTEIN;

ANTIGEN ANTIBODY COMPLEX; ASEPTIC MENINGITIS; ATHEROSCLEROSIS; AUTONOMIC NEUROPATHY; BLOOD VESSEL INJURY; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; CONFUSION; CRANIAL NEUROPATHY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG TOXICITY; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; INFECTION; MENTAL DISEASE; MIGRAINE; MONONEUROPATHY; MOOD DISORDER; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PSYCHOSIS; REVIEW; SEIZURE; SPINAL CORD DISEASE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UREMIA;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PERIPHERAL NERVOUS SYSTEM DISEASES; PROGNOSIS;

EID: 0037115135     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-002-1217-x     Document Type: Review

References (96)

1. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 1990;21:1268-73.
2. Alarcon-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol 1989;16:762-7.
3. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with locallate T-cell activation markers. Lupus 1992;1:111-7.
4. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
5. Andonopoulos AP, Naxakis S, Goumas P, Lygatsikas C. Sensorineural hearing disorders in systemic lupus erythematosus. A controlled study. Clin Exp Rheumatol 1993;13:137-41.
6. Argenbright LW, Barton RW. Interactions ofleukocyte integrins with intercellular adhesion molecule 1 in the production of inflammatory vascular injury in vivo. The Shwartzman reaction revisited. J Clin Invest 1992;89:259-72.
7. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, Lim K, Munoz-Rodriguez FJ, Levy RA, Boue F, Kossert J, Ingelmo M. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195-207.
8. Asherson RA, Derksen RH, Harris EN, Bouma BN, Gharavi AE, Kater L, Hughes GR. Chorea in systemic lupus erythematosus and "lupus-like" disease: Association with antiphospholipid antibodies. Semin Arthritis Rheum 1987;16:253-9.
9. Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996;39:9-22.
10. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: Association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 1981;70:240-6.
11. Bonfa E, Golombek SJ, Kaufinan LD, Skelly S, Weissbach H, Brot N, Elkon KB. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
12. Carlomagno S, Migliaresi S, Ambrosone L, Sannino M, Sanges G. Di Iorio G. Cognitive impairment in systemic lupus erythematosus: A follow-up study. J Neurol 2000;247:273-9.
13. Chen Y, Wu F, Hou L, Ma S, He X. Antiganglioside antibodies in cerebrospinal fluid of children with neuropsychiatric lupus erythematosus, Chin Med J (Engl) 1997;110:594-7.
14. Costallat LT, De Oliveira RM, Santiago MB, Cossermelli W. Samara AM. Neu ropsychiatric manifestations of systemic lupus erythematosus: The value ofanticardiolipin, antigangliosides and antigalactocerebrosides antibodies. Clin Rheumatol 1990;9:489-97.
15. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000;59:243-51.
16. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001;7:1189-93.
17. Denburg JA, Behmann SA. Lymphocyte and neuronal antigens in neuropsychiatric lupus: Presence of an elutable, immunoprecipitable lymphocyte/neuronal 52 kd reactivity. Ann Rheum Dis 1994;53:304-8.
18. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: The role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988;23:3804.
19. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979;8:212-21.
20. Ellison D, Garter K, Heryet A. Esiri M. Intramural platelet deposition in cerebral vasculopathy of systemic lupus erythematosus. J Clin Pathol 1993;46:37-40.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
22. Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989;20:583-91.
23. Galeazzi M, Annunziata P, Sebastiani GD, Bellisai F, Campanella V, Ferrara GB, Font J, Houssiau F, Passiu G, De Ramon GE, Fernandez-Nebro A, Bracci L, Scorza R, Puddu P, Jedryka-Coral A, Smolen J, Tincani A, Carcassi C, Morozzi G, Marcolongo R. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: Clinical, serological, and HLA class 11 gene associations. European Concerted Action on the Immunogenetics of SLE. J Rheumatol 2000;27:135-41.
24. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis. Lupus 1999;8:2206.
25. Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997;36:190-3.
26. Harly JG, Cassell K, Fisk JD. Cognitive function in systemic lupus erythematosus: Results of a 5-year prospective study. Arthritis Rheum 1997;40:1542-3.
27. Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992;19:562-7.
28. Hanly JG, Liang MH. Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann N Y Acad Sci 1997;823:60-8.
29. Hanson VG, Horowitz M, Rosenbluth D, Spiera H, Puszkin S. Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50-kD neuronal membrane protein. J Exp Med 1992;176:565-73.
30. Harbeck RJ, Hoffman AA. Hoffman SA, Shucard DW. Cerebrospinal fluid and the choroid plexus duringacute immune complex disease. Clin Immunol Immunopathol 1979;13:413-25.
31. Hay EM, Black D, Huddy A, Creed F, Tomenson B, Bemstein KM, Holt PJ. Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 1992;35:411-6.
32. Hay EM, Huddy A, Black D, Mbaya P, Tomenson B, Bernstein RM, Lennox, Holt PJ, Creed F. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994;53:298-303.
33. Hirohata S, Hayakawa K. Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999;42:2729-30.
34. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644-9.
35. Houssiau FA, Bukasa K, Sindic CJ, Van Damme J, Van Snick J. Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 1988;71:320-3.
36. How A, Dent PB, Liao SK, Denburg JA. Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1985;28:78995.
37. Hughson MD, McCarty GA, Sholer CM, Brumback RA. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome. Mod Pathol 1993;6:644-53.
38. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998;41:1819-27.
39. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998;17:110-4.
40. Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol 1995;52:1145-9.
41. Keenan PA, Jacobson MW, Soleymani RM, Mayes MD, Stress, ME, Yaldoo DT. The effect on memory of chronic prednisone treatment in patients with systemic disease. Neurology 1996;47:1396-402
42. Klein R, Richter C, Berg PA. Antibodies against central nervous system tissue (anti-CNS) detected by ELISA and western blotting: Marker antibodies for neuropsychiatric manifestations in connective tissue diseases. Autoimmunity 1991;10:133-44.
43. Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 1992;89:1236-41.
44. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature. Ann Rheum Dis 2000;59:120-4
45. Lai NS, Lan JL. Evaluation of cerebrospinal anticardiohpin antibodies in lupus patients with neuropsychiatric manifestations. Lupus 2000;9:353-7.
46. Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies [Review], Arch Neurol 1987;44:876-83.
47. Lie JT. Vasculitis in the antiphospholipid syndrome: Culprit or consort. J Rheumatol 1994;21:3979.
48. Lindal E, Thorlacius S, Steinsson K, Stefansson JG. Psychiatric disorders among subjects with systemic lupus erythematosus in an unselected population. Scand J Rheumatol 1995;24:346-51.
49. Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JA. Serum lymphocyrotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis 1990;49:249-53.
50. Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, Recht PA, Golden B, Cronstein BN. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci U S A 1995;92:8378-82.
51. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
52. Markus HS, Hopkinson N. Migraine and headache in systemic lupus erythematosus and their relationship with antibodies against phospholipids. J Neurol 1992;239:39-42.
53. Matsukawa Y. Sawada S, Hayama T, Usui H, Horie T. Suicide in patients with systemic lupus erythematosus: A clinical analysis of seven suicidal patients. Lupus 1994;3:31-5.
54. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987;2:1175-8.
55. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phosphohpid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein 1 (apolipoprotein H). Proc Nad Acad Sci U S A 1990;87:4120-4.
56. Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology 1994;44(Pt 1):385-93.
57. Naarendorp M, Spiera H, Sudden sensorineural hearing loss in patients with systemic lupus erythematosus orlupus-like syndromes and antiphospholipid antibodies. J Rheumatol 1998;25:589-92.
58. Neumann R, Foster CS. Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus. Retina 1995;15:201-12.
59. Neuwelt CM, Lacks S, Kaye BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41.
60. Omdal R, Husby G, Mellgren SI. Mental health status in systemic lupus erythematosus. Scand J Rheumatol 1995;24:142-5.
61. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
62. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
63. Provenzale JM, Barboriak DP, Gaensler EH, Robertson RL, Mercer B. Lupus-related myelitis: Serial MR findings. AJNR Am J Neuroradiol 1994;15:1911-7.
64. Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest J Jr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2363-8.
65. Rapport MM, Karpiak SE, Mahadik SP. Biological activities of antibodies injected into the brain. Fed Proc 1979;38:2391-6.
66. Robbins ML, Komguth SE, Bell CL, Kalinke T, England D, Turski P, Graziano FM. Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. Combination with anticardiolipin antibody assay and magnetic resonance imaging. Arthritis Rheum 1988;31:623-31.
67. Rojas-Rodriguez J, Garcia-Carrasco M, RamosCasals M, Enriquez-Coronel G, Colchero C, Cervera R, Font J. Catastrophic antiphospholipid syndrome: Clinical description and triggering factors in 8 patients. J Rheumatol 2000;27:238-40.
68. Rood MJ, Havennan JF, van Duinen SG, Breedveld FC. Verschuuren JJ, Huizinga TW. CNS involvement in systemic lupus erythematosus: A case with remarkable histopathological findings. Ann Rheum Dis 2001;60:299-300.
69. Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger, M, Fries JF, Wasner C, Medsger TA Jr, Ziegler G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982;25:612-7.
70. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:115-26.
71. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994;84:2854-67.
72. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: The bimodal pattern revisited. Q J Med 1985;55:87-98.
73. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR. Systemic lupus erythematosus [Review]. Lancet 2001;357:1027-32.
74. Sabbadini MG, Manfredi AA, Bozzolo E, Ferrario L, Rugarli C, Scorza R, Origgi L, Vanoli M, Gambini O, Vanzulli L. Croce D, Campana A, Messa C, Fazio F, Tincani A, Anzola G, Cattaneo R, Padovani A, Gasparotti R, Gerli R, Quartesan R, Piccirilli, M, Farsi A, Emmi E, Passaleva A. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 1999;8:11-9.
75. Sadiq SA, Thomas FP, Kilidireas K, Protopsaltis S, Hays AP, Lee KW, Romas SN, Kumar N, van den BL, Santoro M. The spectrum ofneurologic disease associated with anti-GM1 antibodies. Neurology 1990;40:1067-72.
76. Sato T, Uchiumi T, Ozawa T, Kikuchi M, Nakano M, Kominami R, Arakawa M. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991;18:1681-4.
77. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, Kotzin BL. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991;90:54-62.
78. Shiozawa S, Kuroka Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992;35:417-22.
79. Shortall E, Isenberg D, Newman SP. Factors associated with mood and mood disorders in SLE. Lupus 1995;4:272-9.
80. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992;19:47-52.
81. Straub RH, Jeron A, Kerp L. The pupillary light reflex. 2. Prevalence of pupillary autonomic neuropathy in diabetics using age-dependent and age-independent pupillary parameters. Ophthalmologica 1992;204:143-8.
82. Straub RH, Zeuner M, Lock G, Rath H, Hein R, Scholmerich J, Lang B. Autonomic and sensorimotor neuropathy in patients with systemic lupus erythematosus and systemic sclerosis. J Rheumatol 1996;23:87-92.
83. Sun KH, Liu WT, Tsai CY, Liao TS, Lin WM, Yu CL. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis 1992;51:707-12.
84. Svenungsson E, Andersson M, Brundin L, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001;60:372-9.
85. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
86. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000;9:498-503.
87. Tsokos GC, Tsokos M, le Riche NG, Klippel JH. A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. Semin Arthritis Rheum 1986;16:70-8.
88. Urowitz MB, Gladman DD. How to improve morbidly and mortality in systemic lupos erythematosus. Rheumatology (Oxford) 2000;39:238-44.
89. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993;341:923-5.
90. Ward MM, Studenski S. The time course of acute psychiatric episodes in systemic lupus erythematosus. J Rheumatol 1991;18:535-9.
91. Weiner SM, Klein R, Berg PA. A longitudinal study of autoantibodies against central nervous system tissue and gangliosides in connective tissue diseases. Rheumatol Int 2000;19:83-8.
92. Weiner SM, Otte A, Schumacher M, Brink I, Juengling FD, Sobanksi T, Nitzsche EU, Peter HH. Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus. Lupus 2000;9:386-9.
93. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: A 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
94. Westerman EM, Miles JM, Backonja M, Sundstrom WR. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis Rheum 1992;35:1038-41.
95. Wu R, Huang YH, Elinder LS, Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 1998;18:626-30.
96. Zeballos RS, Fox RI, Cheresh DA, McPherson RA. Anti-glycosphingolipid autoantibodies in rheumatologic disorders. J Clin Lab Anal 1994;8:378-84.